Communiqués Relay Therapeutics, Inc.

Actions

RLAY

US75943R1023

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
6,41 ^USD	+1,75 %		-6,01 %	-41,78 %

14/05	Transcript : Relay Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM
10/05	RELAY THERAPEUTICS, INC. : Barclays désormais positif sur le dossier	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Relay Therapeutics to Participate in Upcoming Investor Conferences	21/05	GL
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024	13/05	GL
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights	02/05	GL
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024	25/04	GL
Relay Therapeutics to Participate in Upcoming Investor Conferences	11/04	GL
Relay Therapeutics to Participate in Three Upcoming Investor Conferences	26/02	GL
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights	22/02	GL
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024	15/02	GL
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024	15/02	AQ
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01/02	GL
Relay Therapeutics Announces $30 Million Private Placement Financing	08/01	GL
Relay Therapeutics Announces $30 Million Private Placement Financing	08/01	AQ
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference	02/01	GL
X-Chem Announces Achievement of Collaboration Milestone	06/12	AQ
Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference	07/11	GL
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights	02/11	GL
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023	26/10/23	GL
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors	12/10/23	GL
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors	12/10/23	AQ
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	18/09/23	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Relay Therapeutics, Inc.

Actions

RLAY

US75943R1023

Communiqués

Filtres